Evidence map›Paper›PMID 31821728›Full record

ArticleMolecular oncology2020

Defective postreplication repair of UV photoproducts in melanoma: a mutator phenotype.

Douglas E Brash, Michael M Seidman

Open access · goldAbstract readComment
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Douglas E BrashDepartments of Therapeutic Radiology and Dermatology and Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0001-7437-9373
Michael M SeidmanLaboratory of Molecular Gerontology, National Institute on Aging, NIH, Baltimore, MD, USA.
National Institute on Aging · USYale Cancer Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Repair of localized DNA damageZIAAG000746 · NIA · NATIONAL INSTITUTE ON AGING · PI SEIDMAN, MICHAEL · 2009 to 2025
$30.0M
Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer RiskR01ES030562 · NIEHS · YALE UNIVERSITY · PI BRASH, DOUGLAS E · 2019 to 2024
$2.6M
Using Clonal and Non-Clonal UV Signature Mutations to Predict Skin Cancer RiskR01CA240602 · NCI · YALE UNIVERSITY · PI BRASH, DOUGLAS E · 2019 to 2023
$2.5M
Repair of localized DNA damageZ01AG000746 · NIA · NATIONAL INSTITUTE ON AGING · PI SEIDMAN, MICHAEL · 2007 to 2008
$607k
Intramural NIH HHS Z01 AG000746Intramural Research Program of the NIH, National Institute on Aging Z01-AG000746-08NCATS NIH HHS UL1 TR001863NCI NIH HHS 1R01CA240602NCI NIH HHS R01 CA240602NIEHS NIH HHS R01 ES030562
6 · The paper itself

Abstract

In this issue, the Gabrielli laboratory and collaborators address the bulky CPD lesions created in DNA when UV joins two adjacent pyrimidines (thymine or cytosine), leading to skin cancers such as melanoma (Pavey S et al. (2019) Mol Oncol). Our understanding of postreplication repair mechanisms for bulky lesions has lagged, and the newly reported predominance of translational control in the UV response has important implications. Image taken from Creative Commons Blacklight bulb in ultraviolet by brx0, licensed under CC BY-SA 2.0. Commentary on.

Indexed as

MelanomaUltraviolet RaysDNADNA RepairHumansPhenotypeDNA

Identifiers

PMID31821728
PMCPMC6944110
OpenAlexW2996392140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.